Treating Cancer with CRISPR?

A federal panel will review the first proposal for the use of the technology to edit human genes for medical purposes.

Jef Akst
Jef Akst

Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf...

View full profile.

Learn about our editorial policies.

Jun 17, 2016

T lymphocyteT lymphocyteFLICKR, NIAIDResearchers at the University of Pennsylvania are hoping to use the CRISPR gene-editing technology to modify T cells isolated from cancer patients before reinjecting the cells as a form of immunotherapy, according to a blog post by Carrie Wolinetz, associate director for science policy at the National Institutes of Health (NIH). Specifically, the Penn team aims to edit two T-cell genes: PD-1, which suppresses the cells’ attack on tumors, and a receptor that can boost the immune system’s ability to fight the cancer. The proposed study will be reviewed by the federal Recombinant DNA Advisory Committee, MIT Technology Review reported.

Two other precision gene editors, TALENs and zinc finger nucleases, are already being tested in the clinic, STAT News reported. Last year, researchers used TALENs to modify T cells for the treatment of leukemia in a British toddler, and Sangamo BioSciences’s therapy based on...

Update (June 22): Yesterday the National Institutes of Health advisory panel approved the University of Pennsylvania team’s proposal to use the CRISPR-Cas9 system to edit patients’ T cells for the treatment of certain cancers. The vote was unanimous, with one member abstaining, The Washington Post reported. The researchers must now seek approval from the US Food and Drug Administration to proceed with their study.

Interested in reading more?

Treating Cancer with CRISPR?



Become a Member of

Receive full access to more than 35 years of archived stories, digital editions of The Scientist Magazine, and much more!
Already a member?